We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Sarepta Therapeutics Inc (SRPT) USD0.0001

Sell:$128.09 Buy:$128.30 Change: $1.19 (0.92%)
Market closed |  Prices as at close on 22 May 2024 | Switch to live prices |
Change: $1.19 (0.92%)
Market closed |  Prices as at close on 22 May 2024 | Switch to live prices |
Change: $1.19 (0.92%)
Market closed |  Prices as at close on 22 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Contact details

215 1st St Ste 415
United States
+1 (617) 2744000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$12.20 billion
Shares in issue:
94.52 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Douglas Ingram
    President, Chief Executive Officer, Director
  • Ian Estepan
    Chief Financial Officer, Executive Vice President
  • Louise Rodino-Klapac
    Executive Vice President, Chief Scientific Officer, Head of R and D
  • Ryan Brown
    Executive Vice President, General Counsel, Corporate Secretary
  • Bilal Arif
    Executive Vice President - Strategy and Operations, Chief Technical Operations Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.